))
41: What is Antimicrobial Resistance?
Manage episode 381527494 series 3305030
Content provided by Deepbridge Capital Discovery Podcast and Deepbridge Capital. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Deepbridge Capital Discovery Podcast and Deepbridge Capital or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Why should we be worried about resistance to antibodies?
Neciah Dorh (CEO at FluoretiQ Limited) joins the Deepbridge Discovery Podcast to discuss his background, why antimicrobial resistance was declared as the biggest health challenge of the 21st century by WHO, what his next steps and goals are and the challenges he has faced.
About FluoretiQ Limited:
We develop diagnostics that are fast, accurate and can be used at the point of care: ensuring the first prescription, is always the right prescription.
Our technologies answer 2 vital questions to ensure effective and sustainable use of antibiotics:
Does the patient have an infection treatable with antibiotics?
NANOPLEX® is an advanced latex agglutination test that can be used to rapidly identify and quantify the cause of infection in 5 minutes.
What will be the most effective antibiotic treatment?
SCFI™ is a phenotypic, real-time and growth-free antibiotic susceptibility test that determines the most effective antibiotic in 30 minutes.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
Neciah Dorh (CEO at FluoretiQ Limited) joins the Deepbridge Discovery Podcast to discuss his background, why antimicrobial resistance was declared as the biggest health challenge of the 21st century by WHO, what his next steps and goals are and the challenges he has faced.
About FluoretiQ Limited:
We develop diagnostics that are fast, accurate and can be used at the point of care: ensuring the first prescription, is always the right prescription.
Our technologies answer 2 vital questions to ensure effective and sustainable use of antibiotics:
Does the patient have an infection treatable with antibiotics?
NANOPLEX® is an advanced latex agglutination test that can be used to rapidly identify and quantify the cause of infection in 5 minutes.
What will be the most effective antibiotic treatment?
SCFI™ is a phenotypic, real-time and growth-free antibiotic susceptibility test that determines the most effective antibiotic in 30 minutes.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
47 episodes
Share
